Therapeutic Advances in Infectious Disease最新文献

{"title":"<i>Mycoplasma hominis</i> prosthetic valve infective endocarditis and endophthalmitis in a renal transplant recipient: a case report.","authors":"Hutton Brandon, Daniel Montelongo-Jauregui, Neeraja Swaminathan","doi":"10.1177/20499361251357405","DOIUrl":"10.1177/20499361251357405","url":null,"abstract":"<p><p><i>Mycoplasma hominis</i> is a rare cause of infective endocarditis, typically reported in immunocompetent patients following valve replacement. We report the first case of post-renal transplant prosthetic valve infective endocarditis and concurrent endophthalmitis caused by <i>M. hominis</i>. A 47-year-old woman with prior aortic valve replacement and renal transplantation presented with fever & atrial fibrillation. She was diagnosed with culture-negative endocarditis complicated by cerebral septic emboli and visual symptoms. Plasma cell-free DNA metagenomic next-generation sequencing identified <i>M. hominis</i>, which was confirmed by culture of aortic abscess tissue. Management included valve replacement surgery and antibiotic therapy with doxycycline and levofloxacin. This case highlights the diagnostic challenges of <i>M. hominis</i> infections, the utility of advanced molecular diagnostics, and the importance of considering <i>M. hominis</i> in immunocompromised patients with culture-negative endocarditis. Donor and recipient screening for <i>M. hominis</i> in recipients with prosthetic heart valves may help prevent infection.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251357405"},"PeriodicalIF":3.8,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular detection of <i>mecA</i> and <i>lukSF-PV</i> in patients with <i>Staphylococcus aureus</i> soft tissue infections in a tertiary hospital setting, Calabar, Nigeria: a cross-sectional study.","authors":"Christian J Ide, Godwin I Ogban, Bassey E Ekeng, Ubleni E Emanghe, Asukwo E Onukak, Anthony A Iwuafor, Ubong A Udoh, Stella T Chukwuma, Emmanuel M Jimmy, Ido E Ukpeh, Tatfeng Y Mirabeau, Daniel Z Egah","doi":"10.1177/20499361251357394","DOIUrl":"10.1177/20499361251357394","url":null,"abstract":"<p><strong>Background: </strong>Panton-Valentine Leukocidin (PVL) is one of the major virulence factors known to be associated with invasive, life-threatening <i>Staphylococcus aureus</i> (<i>S. aureus</i>) soft tissue infections. Several studies have shown that methicillin-resistant <i>S. aureus</i> (MRSA) and methicillin-susceptible <i>S. aureus</i> (MSSA) are carriers of the <i>lukSF-PV</i>; however, data describing their prevalence and distribution in the Nigerian setting are sparse in the literature, and thus informed the need for the current study.</p><p><strong>Objective: </strong>We aimed to detect <i>mecA</i> and analysed the risk factors associated with <i>lukSF-PV</i>-producing <i>S. aureus</i> wound infections.</p><p><strong>Design: </strong>This was a single-centre hospital-based descriptive cross-sectional study conducted between March 2019 and September 2019 at the University of Calabar Teaching Hospital, Calabar, Nigeria.</p><p><strong>Methods: </strong>Aspirates from participants with soft tissue infections were cultured, and all isolates of <i>S. aureus</i> were tested for the presence of <i>lukSF-PV</i> using endpoint polymerase chain reaction. The <i>mecA</i> was also detected, and antibiotic susceptibility testing was performed.</p><p><strong>Results: </strong>Eighty <i>S. aureus</i> isolates were identified from 360 participants. Of the eighty, 47 (58.8%) were MRSA and 10 (12.5%) were <i>lukSF-PV</i>-producing <i>S. aureus</i> strains. Of the ten, six were MSSA and four were MRSA, but the difference was not statistically significant. A significant association was observed between <i>lukSF-PV</i>-producing <i>S. aureus-</i>infected wounds and recurrent skin infections (<i>p</i> = 0.024), as well as working in a day care nursery home (<i>p</i> = 0.0008). The majority of <i>S. aureus</i> isolates were susceptible to tigecycline (76%) and vancomycin (76%), followed by susceptibility to linezolid (72.5%), quinupristin/dalfopristin (67.2%), levofloxacin (38.6%) and erythromycin (11.7%).</p><p><strong>Conclusion: </strong>The prevalence of PVL-positive <i>S. aureus</i> strains causing soft tissue infections in our setting is seemingly high. There is a need for active surveillance of this gene in patients presenting with <i>S. aureus</i> soft tissue infections in our setting, ensure antibiotic susceptibility testing, evaluate the impact of these strains on clinical outcomes and prevent the spread of <i>lukSF-PV</i>-positive <i>S. aureus</i> strains.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251357394"},"PeriodicalIF":3.8,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144683349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding patient and healthcare provider perspectives of uncomplicated urinary tract infection: patient journey, disease management, and the impact of antimicrobial resistance.","authors":"Bhaskar Somani, Maria Sanchez-Grande, Aida Idrissi Kaitouni, Abbe Whittle, Miriam Thun-Winter, Amina Benkiran, Aruni Mulgirigama, Stephen Hughes","doi":"10.1177/20499361251355384","DOIUrl":"10.1177/20499361251355384","url":null,"abstract":"<p><p>Uncomplicated urinary tract infections (uUTIs/acute cystitis) carry a substantial physical and psychological burden that negatively impacts patient quality-of-life, particularly for those who experience recurrent infection. A disconnect can exist between patients and healthcare professionals (HCPs), leading to poor patient-HCP communication, suboptimal treatment, and feelings of frustration and anxiety for many patients. The views of four patient authors with recurrent UTI or chronic uUTI and two HCP authors managing patients with this disease are presented in this Patient Perspectives article. While HCPs recognize both the physical and mental impacts of recurrent uUTIs, most HCPs focus on relieving a patient's physical symptoms, often resulting in the psychological impact being overlooked. Inadequate testing, lengthy diagnostic procedures, and treatment failure caused by antimicrobial resistance (AMR) further exacerbate the problems associated with uUTIs, limiting the effectiveness of treatment options for patients. Enhancing education for patients and HCPs on AMR and the reasons why treatment failure might occur could improve the discourse between HCPs and patients, leading to improvements in the overall patient experience.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251355384"},"PeriodicalIF":3.8,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276519/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lytic bacteriophages as alternative to overcoming antibiotic-resistant biofilms formed by clinically significant bacteria.","authors":"Abdul-Halim Osman, Samuel Darkwah, Fleischer C N Kotey, Adwoa Asante-Poku, Eric S Donkor","doi":"10.1177/20499361251356057","DOIUrl":"10.1177/20499361251356057","url":null,"abstract":"<p><p>Bacterial infections are a major public health threat, with a substantial global burden of ∼5 million deaths in 2019, of which ∼1.27 million were attributed to antibiotic resistance. The formation of bacterial biofilms has significantly enhanced bacterial resistance to antibiotics. Worse still, it increases overall bacterial pathogenesis, contributing to inflammation and potentially to carcinogenesis in humans. Biofilm is implicated in approximately 65% of all bacterial infections and 78.2% chronic wound infections. Alarmingly, about 100-1000-fold increase in antibiotic concentration is required to eradicate bacteria within biofilms, further compromising the health of already ill-patients. Therefore, it is imperative to explore potential antibiofilm agents, especially ones with novel mechanisms of action, to clinically manage inpatient biofilms. Bacteriophage (phage) use is a promising evolutionary approach but is also challenged with potential resistance. Bacteria have developed several antiphage defense mechanisms, some of which exhibit synergistic antiphage activity. In this review, we provide several lines of evidence supporting the efficacy of phages against antibiotic-resistant clinical biofilm-forming bacteria. Observations reveal that phage enzymes disrupt biofilm structural components (e.g., EPS, pectate, and hyaluronic acid) and pave the way for phage infection of naked bacterial cells. We further provide insights into the recent advancements in phage use against biofilm-associated antibiotic-resistant bacteria in patients. Current knowledge shows that phages are rapidly evolving and counteracting antiphage bacterial mechanisms. Here, future perspectives to enhance phages efficacy against biofilm resistance are provided to establish their clinical antibiofilm application. Enhancing the clinical application of phages against biofilms requires addressing bacterial host biofilm resistance and optimizing strategies accordingly. Beyond phage cocktail and phage genetic engineering, conjugating phages with antimicrobial agents (eg., antimicrobial peptides) offers a compelling strategy to enhance phage antibiofilm efficacy.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251356057"},"PeriodicalIF":3.8,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144676030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergence of HCV genotype 6 and its new variants among intravenous drug users in Manipur, a north-eastern state of India.","authors":"Raina Das, Supradip Dutta, Sagnik Bakshi, Aritra Biswas, Shreyasi Nath, Moumita Majumdar, Priya Verma, Upasana Baskey, Shanta Dutta, Provash Chandra Sadhukhan","doi":"10.1177/20499361251351302","DOIUrl":"10.1177/20499361251351302","url":null,"abstract":"<p><strong>Background: </strong>Manipur, a north-eastern state of India, has a high incidence of intravenous drug use with an equally high prevalence of Hepatitis C virus (HCV) infection.</p><p><strong>Objectives: </strong>This cross-sectional study aimed to evaluate the impact of certain risk factors enhancing the susceptibility of acquiring HCV.</p><p><strong>Design: </strong>A total of 1008 participants from various risk groups, from nine districts across the state, were enrolled. Blood samples along with demographic data were collected from the study participants.</p><p><strong>Methods: </strong>HCV RNA was isolated and nested RT-PCR was performed followed by Sanger sequencing for genotyping. Phylogenetic and phylogeographic studies were further conducted.</p><p><strong>Results: </strong>Of the total, 493 (48.90%) samples were HCV sero-reactive. Among the sero-reactive samples, 406 (82.35%) were HCV RNA positive. In case of the subgroup PWID + HIV, sero-reactivity (82.22%) and viremia (90.54%) were observed to be exceptionally high. It was noted that HCV sero-reactivity increased four times in people living with HIV (PLHIV) who continued to inject drugs. Three HCV genotypes and eight subtypes were circulating in this study population.</p><p><strong>Conclusion: </strong>In PLHIV who continued to inject drugs, HCV sero-reactivity increased four-fold. About 40% of the population living with HCV belonged to genotype 6, while genotype 1 showed a noticeable decline. Phylogeographic analyses and spatiotemporal reconstructions revealed that most of the subtypes migrated from far south-east Asian countries like Thailand, Malaysia, Myanmar, and Singapore.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251351302"},"PeriodicalIF":3.8,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perspectives on syringe services programs among patients hospitalized with injection drug use-associated endocarditis: a qualitative study.","authors":"Bailey McInnes, Eunice A Okumu, Maisun M Ansary, Bayla Ostrach, Vivian H Chu, Li-Tzy Wu, Carol Golin, David L Rosen, Asher J Schranz","doi":"10.1177/20499361251353322","DOIUrl":"10.1177/20499361251353322","url":null,"abstract":"<p><strong>Background: </strong>Infective endocarditis (IE) has increased markedly among people who inject drugs (PWID). Harm reduction is a tool to help PWID improve health outcomes and mitigate IE.</p><p><strong>Objectives: </strong>To understand the knowledge, perceptions, past engagement, and planned use of harm reduction services from syringe services programs (SSPs) for PWID hospitalized with IE.</p><p><strong>Design: </strong>Qualitative study of PWID hospitalized with IE.</p><p><strong>Methods: </strong>The research team conducted semi-structured interviews with 16 participants at a large academic hospital from June 2021 to May 2022. Two study personnel coded the interviews and analyzed the data using a combination of structural codes, applied thematic analysis, and thematic comparison.</p><p><strong>Results: </strong>The majority of participants reported past experiences obtaining safe injection supplies from SSPs, and participants generally viewed SSPs as places for facilitating safer injecting practices, receiving sterile supplies, learning about harm reduction, and/or obtaining overdose reversal kits. However, some participants reported being unable to access SSPs because of their rurality, lack of SSP availability, or transportation barriers. In addition, some participants reported a lack of interest in receiving SSP information during hospitalization, believing that it would enable an undesired return to drug use, while others felt that SSP services would not be relevant for them post-hospitalization.</p><p><strong>Conclusion: </strong>Patient past and planned use of harm reduction services offered by SSPs was impacted by geographic barriers to accessibility and patient concerns that SSPs would facilitate an undesired return to drug use. Health systems have an opportunity to improve patient usage of harm reduction services post-hospitalization by improving patient education and integrating harm reduction services as tools of care.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251353322"},"PeriodicalIF":3.8,"publicationDate":"2025-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12256734/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144638379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding GBS infection in pregnancy: exploring adverse maternal and pregnancy outcomes and the prospect of a GBS vaccine.","authors":"Monica Sosa, Linda O Eckert, Alisa Kachikis","doi":"10.1177/20499361251343710","DOIUrl":"10.1177/20499361251343710","url":null,"abstract":"<p><p>Group B streptococcus (GBS) or <i>Streptococcus agalactiae</i> is a beta-hemolytic, Gram-positive coccus that can colonize the genitourinary and gastrointestinal tract of pregnant people. GBS can transition from asymptomatic colonization to pathogenic bacterium which can then lead to adverse pregnancy, maternal and neonatal outcomes. While much of the literature focuses on outcomes affecting the neonate, such as early- and late-onset neonatal sepsis, GBS is also thought to be associated with specific pregnancy and fetal adverse outcomes including preterm birth, preterm premature rupture of membranes, urinary tract infection, endometritis, and maternal sepsis. The objective of this literature review is to further address the known associations of these maternal and pregnancy outcomes, review the current strategies for GBS screening and preventative strategies, and explore the current maternal GBS vaccine candidates in development that may address the limitations of current prevention strategies with intrapartum antibiotic prophylaxis.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251343710"},"PeriodicalIF":3.8,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12254549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, antimicrobial susceptibility patterns, and associated risk factors of <i>Enterococci</i> species in healthcare and community settings in Ethiopia: a systematic review and meta-analysis.","authors":"Zigale Hibstu Teffera, Wubetu Yihunie Belay, Bantayehu Addis Tegegne, Abebe Dagne, Ademe Adugnaw, Habtamu Belew, Yasabe Leykun, Samrawit Tefera, Bewket Mesganaw Shtie, Abebe Yenesew, Abateneh Melkamu, Gashaw Azanaw Amare, Desalegn Abebaw, Yibeltal Akelew, Mohammed Jemal, Baye Ashenef, Mamaru Getinet, Temesgen Baylie, Mihiretie Kiber, Mamaru Tilahun Afework, Tiruzer Hibistu, Kassaye Enchalew","doi":"10.1177/20499361251354905","DOIUrl":"10.1177/20499361251354905","url":null,"abstract":"<p><strong>Background: </strong><i>Enterococci</i> are significant contributors to healthcare-associated infections in Ethiopia.</p><p><strong>Objectives: </strong>This systematic review and meta-analysis synthesize data on the prevalence, antimicrobial susceptibility patterns, and associated risk factors for <i>Enterococcus</i> infections in Ethiopia.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Data sources and methods: </strong>A comprehensive search was conducted in Scopus, PubMed, Web of Science, Cochrane Library, and Google Scholar, covering studies published in English over the past 5 years, with the last search on October 30, 2024. Inclusion criteria targeted original studies on <i>Enterococcus</i> prevalence, resistance, and risk factors in Ethiopian healthcare and community settings. Risk of bias was evaluated using the ROBINS-I tool. Meta-analytic techniques calculated pooled prevalence, log-adjusted odds ratios (log-AORs), and <i>p</i>-values, accompanied by heterogeneity and subgroup analyses.</p><p><strong>Results: </strong>Thirteen studies encompassing 3598 participants (mean age: 29.26 ± 6.6 years) reported a pooled prevalence of 6.67% (95% CI: 5.50-8.85) for <i>Enterococcus</i> species, with substantial regional variation (0.03-55.88). Major risk factors included prolonged hospital stays (OR = 6), catheterization (OR = 3.5), and diabetes (OR = 3.92). The pooled log-AOR was 0.986 (95% CI: 0.214-1.759; <i>p</i> = 0.01). Antimicrobial susceptibility tests identified cephalexin and co-trimoxazole as the most effective antibiotics (100% sensitivity each), while oxacillin, trimethoprim-sulfamethoxazole, and norfloxacin exhibited the highest resistance rates (85.71%, 80.00%, and 80.00%, respectively). Considerable heterogeneity was observed (<i>I</i> ² = 92.31%, τ² = 5882.35).</p><p><strong>Conclusion: </strong>This systematic review and meta-analysis found a 6.67% pooled prevalence of <i>Enterococcus</i> infections in Ethiopia, with high variability in antibiotic resistance and key risk factors such as prolonged hospital stays, catheterization, and diabetes. Effective antibiotics included cephalexin and co-trimoxazole, while high resistance was noted for oxacillin and norfloxacin. The findings emphasize the need for targeted infection control and antimicrobial stewardship.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251354905"},"PeriodicalIF":3.8,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12246523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global \"expiration\" of abacavir in adults with HIV: a rapid review of safety and efficacy concerns challenging its role in modern ART.","authors":"David B Cluck, Daniel B Chastain, Jacob D Lines, William R Short, Diego Cecchini, Juan Ambrosioni, Andrés F Henao-Martínez, Elizabeth M Sherman","doi":"10.1177/20499361251351801","DOIUrl":"10.1177/20499361251351801","url":null,"abstract":"<p><p>Emerging evidence from the REPRIEVE study cohort has further clarified the association between abacavir use and cardiovascular risk. This analysis, along with previous findings, demonstrates a significant elevation in time to first major adverse cardiovascular events (MACE) among adults living with HIV with current or past abacavir exposure. Given the availability of safer, equally effective alternative ART regimens with fewer cardiovascular risks, the continued clinical relevance of abacavir in adults living with HIV should be critically reassessed. Considering these findings, abacavir should be considered an obsolete option for most, if not all, adults living with HIV. This perspective shift emphasizes the importance of selecting ART regimens that optimize long-term cardiovascular health while achieving durable virologic suppression in the modern era of HIV treatment.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251351801"},"PeriodicalIF":3.8,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12246535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Voriconazole versus isavuconazole for invasive aspergillosis: a retrospective analysis in a medically insured U.S. population (2017-2020).","authors":"Sophea Chan, Laura Leigh Stoudenmire, Xianyan Chen, Duna Zhan, Andrés F Henao-Martínez, Daniel B Chastain","doi":"10.1177/20499361251347778","DOIUrl":"10.1177/20499361251347778","url":null,"abstract":"<p><strong>Background: </strong>While isavuconazole (ISA) has demonstrated non-inferiority to voriconazole (VCZ) for invasive aspergillosis (IA) in clinical trials, real-world comparisons are limited.</p><p><strong>Objectives: </strong>To compare treatment completion, adverse events, hospitalizations, and healthcare costs in patients treated with VCZ versus ISA for IA.</p><p><strong>Design: </strong>Retrospective cohort study using Merative MarketScan claims data (2017-2020).</p><p><strong>Methods: </strong>Adults (⩾18 years) diagnosed with IA (International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes) who received VCZ or ISA monotherapy were included. Treatment completion was defined as ⩾42 days of therapy. Descriptive statistics and logistic regression were used to assess outcomes and predictors of antifungal selection, adverse events, hospitalizations, and treatment completion.</p><p><strong>Results: </strong>Among 335 patients, 84% (<i>n</i> = 282) received VCZ and 16% (<i>n</i> = 53) received ISA. Baseline characteristics were comparable, although the VCZ group had higher Medicaid enrollment, and the ISA group had more patients with malignancy. Treatment completion rates were comparable (92% each, <i>p</i> = 1), as were median treatment durations (VCZ: 120 days, ISA: 112 days, <i>p</i> = 0.95). Adverse event rates were not significantly different (VCZ: 49%, ISA: 60%, <i>p</i> = 0.18), but CNS-related events occurred more frequently with ISA (16% vs 9%, <i>p</i> = 0.32). VCZ was associated with lower outpatient pharmacy costs (median $1,596.68 vs $11,000.66, <i>p</i> < 0.001) and total hospitalization costs (median $40,681.89 vs $121,545.89, <i>p</i> = 0.01). Malignancy was associated with lower odds of receiving VCZ (OR 0.30, <i>p</i> = 0.001), and younger age predicted higher odds of treatment incompletion (OR 0.97, <i>p</i> = 0.035). Female sex was associated with increased adverse event risk. Notably, VCZ use was not associated with increased adverse events or treatment incompletion.</p><p><strong>Conclusion: </strong>VCZ was prescribed five times more frequently than ISA for IA, despite similar treatment durations and completion rates. VCZ was associated with lower costs and did not increase the risk of adverse events or treatment discontinuation. These findings suggest that VCZ remains commonly used and potentially more cost-effective treatment option for IA.</p>","PeriodicalId":46154,"journal":{"name":"Therapeutic Advances in Infectious Disease","volume":"12 ","pages":"20499361251347778"},"PeriodicalIF":3.8,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205192/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}